Patents Examined by Jeffrey S. Lundgren
  • Patent number: 10993947
    Abstract: The present invention is relates to a compound of formula (I), wherein X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of X1, X2 and X3 are N; Y is N or CH; W is H or F; with the proviso that when W is F, then X1, X2 and X3 are N; R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I); and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures wherein the arrows denote the bonds in formula (II); or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: May 4, 2021
    Assignee: TORQUR
    Inventors: Doriano Fabbro, Paul Hebeisen, Petra Hillmann-Wuellner, Anton Stuetz, John T. Seykora, Florent Beaufils
  • Patent number: 10993929
    Abstract: The addition of a salt to an ALA formulation that is dissolved in the mouth unexpectedly significantly reduces the degree of burning or irritation from ALA exposure during administration. This invention is particularly useful for an oral dissolved form of administration due to the extended time of ALA exposure that is possible with such formulations. The salt-inclusive formulations of the invention can increase efficacy of the ALA administration, reduce negative side effects, or both.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 4, 2021
    Assignee: Molecular Product Management, LLC
    Inventor: William C. Zolentroff
  • Patent number: 10987293
    Abstract: The present invention relates to a composition for skin external application. Specifically, a composition for skin external application comprising a stably formed lamella liquid crystal phase can be provided according to the present invention. In addition, according to the present invention, the composition can provide excellent skin moisturizing and skin barrier strengthening effects upon application on the skin, as well as act effectively as an agent for a cannabinoid type 1 receptor, such that it is expected that the present invention can provide a very effective effect for treatment or improvement of skin diseases and mental disorders associated with skin diseases.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: April 27, 2021
    Assignee: DR. RAYMOND LABORATORIES, INC.
    Inventors: Sin Hee Lee, Byeong Deog Park
  • Patent number: 10987323
    Abstract: The object of the present invention is the combination of palmitoylethanolamide (PEA) and lycopene, and/or pharmaceutically acceptable salts and/or derivatives thereof, the pharmaceutical formulations comprising the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, optionally together with at least one pharmacologically acceptable excipient, and the use of the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, and of the formulations comprising such a combination, in the treatment of inflammatory diseases.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: April 27, 2021
    Assignee: ALI RESEARCH SRLS
    Inventors: Raffaele Migliaccio, Antonella Sardei, Carmela Migliaccio
  • Patent number: 10980886
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: April 20, 2021
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Patent number: 10980783
    Abstract: Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 20, 2021
    Assignee: KNOPP BIOSCIENCES LLC
    Inventors: Michael E. Bozik, Gregory Hebrank, Wildon Farwell, Thomas Petzinger, Jr., Steven Dworetzky
  • Patent number: 10973780
    Abstract: Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Assignee: Bexson Biomedical, Inc.
    Inventors: Jeffrey Becker, Gregg Peterson, Jason Wallach
  • Patent number: 10975066
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking, Adrian Hall, Malcolm Maccoss
  • Patent number: 10973808
    Abstract: A bowel cleansing composition includes as a first cleansing ingredient, a specific sugar alcohol such as xylitol, sorbitol, etc., as a second cleansing ingredient glycerol, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol, as a second cleansing ingredient ascorbic acid or a mixture of ascorbic acid and a salt of ascorbic acid, as a third cleansing ingredient picosulfate, and an aqueous solvent, wherein the concentration of the first cleansing ingredient is 10 g/L to 500 g/L based on the total composition, the concentration of the second cleansing ingredient is 15 g/L to 500 g/L based on the total composition, the concentration of the third cleansing ingredient is 1 mg/L to 100 mg/L based on the total composition, and the volume of the aqueous solvent is 0.1 L to 1.0 L.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 13, 2021
    Inventors: Yoon Sik Kang, Chung Yoon Shin, Hyun Suk Kang, Hyun Yee Kang
  • Patent number: 10973812
    Abstract: A method for treating a subject having, or at risk of having, ataxia, generally includes administering to the subject an amount of a composition comprising a cholecystokinin receptor (Cck1R) agonist effective to ameliorate at least one symptom or clinical sign of ataxia.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 13, 2021
    Assignees: Regents of the University of Minnesota, Baylor College of Medicine
    Inventors: Harry T. Orr, Emily A. L. Wozniak, Huda Y. Zoghbi
  • Patent number: 10973228
    Abstract: [Problem] The object is to obtain cosmetics which do not show primary skin irritation or sensitization, and do not impart any unpleasant sensation such as sharp pain or prickly sensation when employed as a cosmetic, with the lowest possible inclusion of preservative/fungicide. [Solution] Antimicrobial low-irritant cosmetics characterized in that they contain one or two or more tropolone derivative(s) and one or two or more polyhydric alcohol(s) in quantities which have an anti-microbial effect and low skin irritancy.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: April 13, 2021
    Assignee: ISP INVESTMENTS LLC
    Inventors: Nadia Konate, Andrea Wingenfeld
  • Patent number: 10975048
    Abstract: The invention belongs to the field of biomedical research involving the 1,3,4-selenyldiazo derivatives that have cell protective activity. Because there are not so many heterocyclic selenium compounds, we synthesized a new type of selenium analog of BPTES. As the isoacceptor of BPTES, the compounds have antitumor activity, anti-oxidation and cell protection function. Currently many drugs contain the thiodiazo motif, so synthesis of selenyldiazo functional group could further optimize these drugs and are important in new drug development and application.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 13, 2021
    Inventors: Benfang Helen Ruan, Jennifer Jin Ruan
  • Patent number: 10973821
    Abstract: A pharmaceutical composition suitable for oral administration comprising particles of 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- oxoacetamideis provided. Also provided is a pharmaceutical composition suitable for parenteral administration wherein the composition comprises 2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide. The compositions are useful in the treatment of fungal infection in a subject in need thereof.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: April 13, 2021
    Assignee: F2G LIMITED
    Inventors: Derek Law, Graham Edward Morris Sibley
  • Patent number: 10940132
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: March 9, 2021
    Assignee: AFECTA PHARMACEUTICALS, INC.
    Inventor: Bruce Kovacs
  • Patent number: 10940133
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 9, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Katayoun Zomorodi
  • Patent number: 10940126
    Abstract: Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 9, 2021
    Inventors: Camilla Svensson, Lars Klareskog, Vivianne Malmstrom, Anca Catrina
  • Patent number: 10934302
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 2, 2021
    Assignee: Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien
  • Patent number: 10933045
    Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 2, 2021
    Assignee: LACHESIS BIOSCIENCES LIMITED
    Inventor: Timothy Matthias Morgan
  • Patent number: 10933068
    Abstract: Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 2, 2021
    Assignee: Sonic Master Limited
    Inventors: Amanda Rickard, Anabel De La Garza, Uli Schmidt, Alexander Kiselyov
  • Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend